School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.
Department of Chinese Medicine, E-Da Cancer Hospital, Kaohsiung, Taiwan.
Cell Transplant. 2020 Jan-Dec;29:963689720927398. doi: 10.1177/0963689720927398.
Osteoporotic fracture is the main complication of osteoporosis (OP) and accounts for millions of injuries annually. Local intervention by intra-marrow injection has been a good option for preventing osteoporotic bone loss when the osteoporotic femoral fracture has been treated. In this study, tail vein transplantations were examined to evaluate the cell-based therapeutic approach for treating OP with adipose-derived stem cells (ADSCs) and platelet-rich fibrin releasates (PRFr) in an ovariectomized (OVX) mice model. Thirty-six 12-wk-old female ICR mice were randomly divided into six groups: untreated control; sham-operated; OVX-control; OVX-ADSCs; OVX-PRFr; and OVX-ADSCs+PRFr. Starting 8 wk after ovariectomy, the OVX mice received tail vein injections once each week for four consecutive weeks, then were evaluated radiographically and histopathologically 8 wk after the first injection. We also assessed changes to bone trabeculae in the proximal tibial growth plate. In OVX mice treated with ADSCs or PRFr alone, or with a combination of ADSCs and PRFr, the trabecular bone mineral density (BMD), bone volume ratios (BV/TV), and numbers (Tb.N) in the proximal tibia areas were significantly higher than that in the OVX-control group. Significant differences between OVX-treated mice and OVX controls were found for trabecular separation, but not for trabecular thickness. These results indicate that ADSCs or PRFr treatment enhances bone microarchitecture in OP. The treatment of bone loss of OVX mice with ADSCs+PRFr induced greater bone consolidation with bone tissue production ( < 0.01) when compared to the others. Thus, we conclude that the transplantation of ADSCs combined with PRFr might provide an alternative strategy for the treatment of various bone disorders in OP with an unlimited source of cells and releasates.
骨质疏松性骨折是骨质疏松症（OP）的主要并发症，每年导致数百万人受伤。当治疗骨质疏松性股骨骨折时，骨髓内注射的局部干预已成为预防骨质疏松性骨丢失的一种较好选择。在这项研究中，通过尾静脉移植来评估脂肪来源的干细胞（ADSCs）和富含血小板的纤维蛋白释放物（PRFr）在去卵巢（OVX）小鼠模型中治疗 OP 的细胞治疗方法。36 只 12 周龄雌性 ICR 小鼠被随机分为六组：未处理对照组；假手术组；OVX 对照组；OVX-ADSCs 组；OVX-PRFr 组；和 OVX-ADSCs+PRFr 组。从去卵巢后 8 周开始，OVX 小鼠每周接受一次尾静脉注射，连续四周，然后在第一次注射后 8 周进行放射学和组织病理学评估。我们还评估了近端胫骨生长板中骨小梁的变化。在单独用 ADSCs 或 PRFr 治疗，或用 ADSCs 和 PRFr 联合治疗的 OVX 小鼠中，胫骨近端区域的骨小梁骨密度（BMD）、骨体积比（BV/TV）和数量（Tb.N）明显高于 OVX 对照组。与 OVX 对照组相比，OVX 治疗小鼠的骨小梁分离存在显著差异，但骨小梁厚度无差异。这些结果表明，ADSCs 或 PRFr 治疗可增强 OP 中的骨微观结构。与其他组相比，用 ADSCs+PRFr 治疗 OVX 小鼠的骨丢失可诱导更大的骨整合和骨组织生成（<0.01）。因此，我们得出结论，移植 ADSCs 联合 PRFr 可能为 OP 中的各种骨疾病提供一种替代治疗策略，具有无限的细胞和释放物来源。
